RUFFOLO ROBERT R — SEC insider filings
SEC reporting owner CIK 1187308. 14 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2020-12-07 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 6,750 shares, $69,930 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 6,750 shares @ $10.36 ($69,930) in Sigilon Therapeutics, Inc., filed 2021-07-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Sigilon Therapeutics, Inc. (SGTX) | Director | 6 | — | 1 leg · 6,750 sh · $69,930 | 9 |
| LB PHARMACEUTICALS INC (LBRX) | Director | 2 | — | — | 8 |
| Elicio Therapeutics, Inc. (ELTX) | Director | 4 | — | — | 4 |
| Aridis Pharmaceuticals, Inc. (ARDS) | Director | 2 | — | — | 2 |
Insider filings — RUFFOLO ROBERT R
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | LB PHARMACEUTICALS INC (LBRX) | Disposition to issuer (D): 1,792 (derivative) · Grant/award (A): 1,792 (derivative) · Disposition to issuer (D): 717 (derivative) · Grant/award (A): 717 (derivative) · Disposition to issuer (D): 10,757 (derivative) · Grant/award (A): 10,757 (derivative) · +1 more | EDGAR |
| 2025-05-20 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2023-08-11 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Disposition to issuer (D): 683 (derivative) @ $6.64 · Disposition to issuer (D): 683 (derivative) @ $5.00 · Disposition to issuer (D): 3,754 (derivative) @ $7.51 | EDGAR |
| 2023-05-22 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 8,888 (derivative) @ $0 | EDGAR |
| 2022-12-07 | 4 | Aridis Pharmaceuticals, Inc. (ARDS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-05-27 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 8,888 (derivative) @ $0 | EDGAR |
| 2021-10-05 | 4 | Aridis Pharmaceuticals, Inc. (ARDS) | Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Option exercise (M): 6,750 @ $0.57 · Sale (S): 6,750 @ $10.36 · Option exercise (M): 6,750 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 8,888 (derivative) @ $9.97 | EDGAR |
| 2020-12-07 | 4 | Sigilon Therapeutics, Inc. (SGTX) | Grant/award (A): 8,888 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1187308 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs